Analyst Ratings for [NUVB] Nuvation Bio Inc

3/27/24	Upgrades	Hold Buy	X
NUVB Nuvation Bio Jefferies
$1.40 $10
3/26/24	Upgrades	Neutral Buy	X
NUVB Nuvation Bio BTIG Research
$5
1/6/23	Downgrades	Buy Hold	X
NUVB Nuvation Bio Jefferies
$5 $2
8/2/22	Downgrades	Outperform Mkt Perform	X
NUVB Nuvation Bio BMO Capital Markets
$8 $2.50
8/2/22	Downgrades	Buy Neutral	X
NUVB Nuvation Bio BTIG Research
5/4/22	Initiated	Buy	X
NUVB Nuvation Bio H.C. Wainwright
$14
10/15/21	Resumed	Buy	X
NUVB Nuvation Bio BTIG Research
$16
4/6/21	Initiated	Outperform	X
NUVB Nuvation Bio RBC Capital Mkts
$15
3/8/21	Initiated	Outperform	X
NUVB Nuvation Bio BMO Capital Markets
$16
3/8/21	Initiated	Buy	X
NUVB Nuvation Bio BTIG Research
$16
3/8/21	Initiated	Outperform	X
NUVB Nuvation Bio Cowen
3/8/21	Initiated	Buy	X
NUVB Nuvation Bio Jefferies
$20
3/8/21	Initiated	Outperform	X
NUVB Nuvation Bio Wedbush
$20

NUVB Nuvation Bio Inc

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Nuvation Bio Inc., a biopharmaceutical company, focuses on the development of therapies for oncology. Its portfolio includes various oncology programs with multiple drug development candidates. Nuvation Bio Inc.was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. The company was founded in 2018 and is based in New York, New York with an additional office in San Francisco, California.